FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
14 letters match. Newest first.
-
BiologicsCentral Coast Multispecialty Medical Group, Inc.
FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.
High risk -
BiologicsConceive Fertility Center
FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.
High risk -
BiologicsLouisville Reproductive Center
Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.
High risk -
BiologicsGreen Valley Fertility Partners
FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.
High risk -
BiologicsLux Therapeutics LLC dba Ponya Therapeutics LLC
FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.
High risk -
BiologicsInVia Fertility Specialists, PLLC
FDA warned InVia Fertility Specialists over reproductive tissue donor eligibility and missing infectious disease testing.
High risk -
BiologicsNew Mexico Lions Sight Conservation Foundation, Inc. dba New Mexico Lions Eye Bank
FDA warns New Mexico eye bank over distributing eye tissue from two donors with sepsis.
High risk -
BiologicsIndiana Lions Eye Bank, Inc. dba VisionFirst Indiana Lions Eye Bank
Indiana Lions Eye Bank distributed ocular tissue from donors with sepsis after failing to screen them as ineligible.
High risk -
BiologicsAkan Biosciences, Inc.
FDA warned Akan Biosciences over unapproved Ayama injectable and donor-screening failures.
High risk -
BiologicsWashington Fertility Center
FDA warned Washington Fertility Center about incomplete donor eligibility screening and testing for oocytes, semen, and embryos.
High risk -
BiologicsThe New Hope Center for Reproductive Medicine
FDA warns Virginia Beach fertility center over incomplete donor screening and testing for reproductive tissue.
High risk -
BiologicsInvitrx Therapeutics, Inc.
Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.
High risk -
BiologicsZhang Medical P.C. dba New Hope Fertility Center
New Hope Fertility Center failed to properly screen and test oocyte and semen donors for communicable diseases, FDA says.
High risk -
BiologicsCooper Institute
FDA warned Houston fertility clinic Cooper Institute that it failed to test and screen oocyte donors for infectious diseases.
High risk